Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
NCT06073184 on ClinicalTrials.gov · last registry update 2026-10-05
Recruiting now, toward 71 participants. Due to report February 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Assessment of Complete Pathologic Response. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 2 times since then.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- GynOncTrials
- Sponsor type
- Other
- Enrollment
- 71
- Started
- 2026-09-17
- Primary completion
- 2029-02 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-05 | Reporting date moved | 2027-02 → 2029-02 24 months later |
| 2026-10-05 | Status changed | NOT_YET_RECRUITING → RECRUITING |
Primary outcome
Assessment of Complete Pathologic Response
Conditions studied
Endometrial Cancer · Atypical Hyperplasia · Fertility Perservation
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.